Conatus Pharmaceuticals (NASDAQ:CNAT) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, March 7th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.
Conatus Pharmaceuticals (NASDAQ CNAT) traded down $0.01 during midday trading on Thursday, reaching $5.19. 292,318 shares of the company’s stock traded hands, compared to its average volume of 516,162. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.69 and a quick ratio of 2.69. Conatus Pharmaceuticals has a 1 year low of $3.88 and a 1 year high of $9.40. The company has a market capitalization of $155.73, a price-to-earnings ratio of -6.41 and a beta of 1.24.
An institutional investor recently bought a new position in Conatus Pharmaceuticals stock. State Street Corp acquired a new stake in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 362,811 shares of the biotechnology company’s stock, valued at approximately $2,092,000. State Street Corp owned about 1.21% of Conatus Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 38.95% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3231786/conatus-pharmaceuticals-cnat-set-to-announce-quarterly-earnings-on-wednesday.html.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.